Company facts
- Industry
- Pharmaceutical Preparations
- Headquarters
- Radnor, Pennsylvania
- Most recent report
- 10-Q, filed Aug 11, 2026
- Filings on record
- 388 filings
- On EDGAR
- CIK 1933414
- Fiscal year ends
- December
- Filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
Financials 8 of 15
News 8 of 46
Prospectuses and Registrations 8 of 16
- 424B5 Prospectus supplement for an offering Jun 3, 2026
- S-8 Registration statement for an employee plan Feb 13, 2026
- S-3ASR Automatic shelf registration Nov 10, 2025
- 424B5 Prospectus supplement for an offering Sep 3, 2025
- 424B5 Prospectus supplement for an offering Sep 2, 2025
- 424B5 Prospectus supplement for an offering Mar 12, 2025
- 424B5 Prospectus supplement for an offering Mar 10, 2025
- S-8 Registration statement for an employee plan Feb 14, 2025
Proxies 6
Ownership 8 of 282
- 4 Insider reported a trade Aug 25, 2026
- 144 Notice of a proposed sale of restricted stock Aug 21, 2026
- 144 Notice of a proposed sale of restricted stock Aug 17, 2026
- 144 Notice of a proposed sale of restricted stock Aug 13, 2026
- 4 Insider reported a trade Aug 12, 2026
- 3 Insider reported their initial holding Aug 12, 2026
- 4 Insider reported a trade Aug 12, 2026
- 144 Notice of a proposed sale of restricted stock Aug 10, 2026
Other 8 of 23
- ARS Annual report sent to shareholders Apr 10, 2026
- S-3MEF Sep 2, 2025
- ARS Annual report sent to shareholders Apr 9, 2025
- EFFECT Notice that a registration became effective Apr 11, 2024
- CORRESP Reply to SEC staff Apr 9, 2024
- ARS Annual report sent to shareholders Apr 9, 2024
- UPLOAD Comment letter from SEC staff Mar 26, 2024
- SEC STAFF LETTER Feb 15, 2023
Everything here comes from Mineralys Therapeutics, Inc.'s own filings on SEC EDGAR. The filing list is rechecked every hour.